Sarepta Therapeutics, Inc.

Key Statistics

Recent News

• Is Sarepta (SRPT) Using New Equity Plans To Quietly Redefine Its Post‑Profitability Playbook? Simply Wall St.

  Sarepta Therapeutics recently filed a US$341.99 million shelf registration for 7,786,841 common shares tied to employee stock ownership, alongside shareholder approval of new 2026 equity incentive and

• All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy Zacks

  Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

• SRPT vs. ARGX: Which Stock Is the Better Value Option? Zacks

  SRPT vs. ARGX: Which Stock Is the Better Value Option?

• Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy Insider Monkey

  Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 6, Sarepta Therapeutics Inc. (NASDAQ:SRPT) delivered impressive first-quarter results

• Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report? Zacks

  Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

• In Solid Cash Position, Sarepta Therapeutics Inc (SRPT) Outlines 2026 Priorities Insider Monkey

  Sarepta Therapeutics Inc (NASDAQ:SRPT) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. 36 elite hedge funds have positions in Sarepta Therapeuti

• Assessing Sarepta Therapeutics (SRPT) Valuation After Recent Share Price Weakness Simply Wall St.

  Recent performance snapshot Sarepta Therapeutics (SRPT) has drawn investor attention after a prolonged slide in the stock, with shares down about 17% over the past month and roughly 11% over the past

• KROS Turns to Next Wave of TGF-Beta Muscle Therapies Zacks

  Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.